Difference between revisions of "Capivasertib (Truqap)"
Jump to navigation
Jump to search
m (Jwarner moved page Capivasertib (AZD-5363) to Capivasertib (Truqap): FDA approval) |
m |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=688304 NCI Drug Dictionary]: A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AKT inhibitor AZD5363 binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=688304 NCI Drug Dictionary]: A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AKT inhibitor AZD5363 binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. | ||
| − | == | + | ==Diseases for which it is established== |
| − | + | *[[Breast cancer]] | |
| − | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *2023-11-16: Approved with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting. ''(Based on CAPItello-291)'' | + | *2023-11-16: Approved with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic [[breast cancer]] with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting. ''(Based on CAPItello-291)'' |
| − | *2023-11-16: Approved with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following recurrence on or within 12 months of completing adjuvant therapy. ''(Based on CAPItello-291)'' | + | *2023-11-16: Approved with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic [[breast cancer]] with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following recurrence on or within 12 months of completing adjuvant therapy. ''(Based on CAPItello-291)'' |
==Also known as== | ==Also known as== | ||
| Line 18: | Line 17: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| + | [[Category:Protein expression-specific medications]] | ||
[[Category:AKT1 inhibitors]] | [[Category:AKT1 inhibitors]] | ||
Latest revision as of 17:19, 26 January 2024
Mechanism of action
From the NCI Drug Dictionary: A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AKT inhibitor AZD5363 binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism.
Diseases for which it is established
History of changes in FDA indication
- 2023-11-16: Approved with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting. (Based on CAPItello-291)
- 2023-11-16: Approved with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following recurrence on or within 12 months of completing adjuvant therapy. (Based on CAPItello-291)
Also known as
- Code name: AZD-5363
- Brand name: Truqap